HALOZYME THERAPEUTICS, INC. Dilutive Share Adjustment
HALOZYME THERAPEUTICS, INC. (HALO) reported Dilutive Share Adjustment of 5.26 million shares for the 12-month period ending 2020-12-31, per its 10-K filed 2021-02-23.
Discontinued › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment · last filed 2021-02-23
- HALOZYME THERAPEUTICS, INC. weighted average number diluted shares outstanding adjustment for the quarter ending 2020-12-31 was 10.84M shares.
- HALOZYME THERAPEUTICS, INC. weighted average number diluted shares outstanding adjustment for the quarter ending 2020-09-30 was 5.50M shares.
- HALOZYME THERAPEUTICS, INC. weighted average number diluted shares outstanding adjustment for the quarter ending 2020-06-30 was 2.15M shares.
- HALOZYME THERAPEUTICS, INC. weighted average number diluted shares outstanding adjustment for the quarter ending 2020-03-31 was 0.00 shares, a 100.00% decline year-over-year.
- HALOZYME THERAPEUTICS, INC. weighted average number diluted shares outstanding adjustment for fiscal 2020 was 5.26M shares.
- HALOZYME THERAPEUTICS, INC. weighted average number diluted shares outstanding adjustment for fiscal 2019 was 0.00 shares.
- HALOZYME THERAPEUTICS, INC. weighted average number diluted shares outstanding adjustment for fiscal 2018 was 0.00 shares, a 100.00% decline from fiscal 2017.
- HALOZYME THERAPEUTICS, INC. weighted average number diluted shares outstanding adjustment for fiscal 2017 was 2.65M shares.
| Period end | Weighted Average Number Diluted Shares Outstanding Adjustment 3 month | Weighted Average Number Diluted Shares Outstanding Adjustment 6 month | Weighted Average Number Diluted Shares Outstanding Adjustment 9 month | Weighted Average Number Diluted Shares Outstanding Adjustment 12 month |
|---|---|---|---|---|
| 2020-12-31 | 10.84M shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-23 | 8.17M shares derived: average of 2 quarters · filed 2021-02-23 | 6.16M shares derived: average of 3 quarters · filed 2021-02-23 | 5.26M shares 10-K · filed 2021-02-23 |
| 2020-09-30 | 5.50M shares 10-Q · filed 2020-11-02 | 3.83M shares derived: average of 2 quarters · filed 2020-11-02 | 3.40M shares 10-Q · filed 2020-11-02 | 1.91M shares derived: average of 4 quarters · filed 2021-02-23 |
| 2020-06-30 | 2.15M shares 10-Q · filed 2020-08-10 | 2.27M shares 10-Q · filed 2020-08-10 | 716.33K shares derived: average of 3 quarters · filed 2021-02-23 | 537.25K shares derived: average of 4 quarters · filed 2021-02-23 |
| 2020-03-31 | 0.00 shares 10-Q · filed 2020-05-11 | 0.00 shares derived: average of 2 quarters · filed 2021-02-23 | 0.00 shares derived: average of 3 quarters · filed 2021-02-23 | 0.00 shares derived: average of 4 quarters · filed 2021-02-23 |
| 2019-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-23 | 0.00 shares derived: average of 2 quarters · filed 2021-02-23 | 0.00 shares derived: average of 3 quarters · filed 2021-02-23 | 0.00 shares 10-K · filed 2021-02-23 |
| 2019-09-30 | 0.00 shares 10-Q · filed 2020-11-02 | 0.00 shares derived: average of 2 quarters · filed 2020-11-02 | 0.00 shares 10-Q · filed 2020-11-02 | 682.75K shares derived: average of 4 quarters · filed 2021-02-23 |
| 2019-06-30 | 0.00 shares 10-Q · filed 2020-08-10 | 0.00 shares 10-Q · filed 2020-08-10 | 910.33K shares derived: average of 3 quarters · filed 2021-02-23 | 682.75K shares derived: average of 4 quarters · filed 2021-02-23 |
| 2019-03-31 | 2.73M shares 10-Q · filed 2020-05-11 | 1.37M shares derived: average of 2 quarters · filed 2021-02-23 | 910.33K shares derived: average of 3 quarters · filed 2021-02-23 | |
| 2018-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-23 | 0.00 shares derived: average of 2 quarters · filed 2021-02-23 | 0.00 shares 10-K · filed 2021-02-23 | |
| 2018-09-30 | 0.00 shares 10-Q · filed 2018-11-06 | 0.00 shares 10-Q · filed 2018-11-06 | ||
| 2018-03-31 | 0.00 shares 10-Q · filed 2019-05-07 | 5.30M shares derived: average of 2 quarters · filed 2020-02-24 | 4.21M shares derived: average of 3 quarters · filed 2020-02-24 | |
| 2017-12-31 | 10.60M shares derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-24 | 6.32M shares derived: average of 2 quarters · filed 2020-02-24 | 2.65M shares 10-K · filed 2020-02-24 | |
| 2017-09-30 | 2.05M shares 10-Q · filed 2018-11-06 | 0.00 shares 10-Q · filed 2018-11-06 | ||
| 2016-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-21 | 0.00 shares derived: average of 2 quarters · filed 2019-02-21 | 0.00 shares 10-K · filed 2019-02-21 | |
| 2016-09-30 | 0.00 shares 10-Q · filed 2017-11-07 | 0.00 shares 10-Q · filed 2017-11-07 | ||
| 2015-12-31 | 0.00 shares 10-K · filed 2018-02-20 | |||
| 2015-06-30 | 8.36M shares 10-Q · filed 2015-08-10 | 0.00 shares 10-Q · filed 2015-08-10 | ||
| 2014-06-30 | 0.00 shares 10-Q · filed 2015-08-10 | 0.00 shares 10-Q · filed 2015-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |